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Objective: To review published evidence regarding the cost effectiveness of multi-component 
COPD programs and to illustrate how potentially cost effective programs can be identiﬁ  ed.
Methods: Systematic search of Medline and Cochrane databases for evaluations of multi-
component disease management or chronic care programs for adults with COPD, describing 
process, intermediate, and end results of care. Data were independently extracted by two review-
ers and descriptively summarized.
Results: Twenty articles describing 17 unique COPD programs were included. There is little 
evidence for signiﬁ  cant improvements in process and intermediate outcomes, except for increased 
provision of patient self-management education and improved disease-speciﬁ  c knowledge. 
Overall, the COPD programs generate end results equivalent to usual care, but programs con-
taining  3 components show lower relative risks for hospitalization. There is limited scope for 
programs to break-even or save money.
Conclusion: Identifying cost effective multi-component COPD programs remains a challenge 
due to scarce methodologically sound studies that demonstrate signiﬁ  cant improvements on 
process, intermediate and end results of care. Estimations of potential cost effectiveness of 
speciﬁ  c programs illustrated in this paper can, in the absence of ‘perfect data’, support timely 
decision-making regarding these programs. Nevertheless, well-designed health economic studies 
are needed to decrease the current decision uncertainty.
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Introduction
Chronic care programs for people with chronic obstructive pulmonary disease (COPD), 
such as the chronic care model1 and disease management programs2 are increasingly 
implemented in daily health care3,4 in response to the growing burden of COPD on 
societies worldwide.5 The aim of these programs is, generally, to improve processes 
and outcomes of care whilst making a more efﬁ  cient use of scarce health care resources, 
or even generate cost savings.
The disease management approach as described by the Disease Management Asso-
ciation of America (DMAA) highlights three components: the central care delivery 
and leadership roles of the primary care physician; the critical importance of patient 
activation, involvement and personal responsibility; and the patient focus and capacity 
expansion of care coordination provided through wellness, disease and chronic care 
management programs.2 The chronic care model (CCM) identiﬁ  es essential components 
that encourage high-quality chronic disease care, involving the community and health 
system and including self-management support, delivery system design, decision sup-
port, and clinical information systems.6
Notwithstanding the intuitive appeal of these approaches, the current evidence 
regarding their efﬁ  cacy, effectiveness and cost effectiveness is severely limited by the 
amount and quality of well-designed studies and the evidence that has been published International Journal of COPD 2009:4 88
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so far reveals results that are far below expectations.7 Indeed, 
the systematic reviews of Weingarten,8 Ofman,9 and Mattke10 
consistently show that disease management is less effective 
for COPD than it is for chronic conditions such as diabetes, 
congestive heart failure and depression.
By speciﬁ  cally focussing on COPD, however, the sys-
tematic review of Adams and colleagues11 demonstrated that 
patients who received two or more CCM components had 
lower rates of hospitalizations and emergency/unscheduled 
visits, and shorter length of hospital stay compared with 
control groups. This may indicate that, despite earlier less 
encouraging ﬁ  ndings, a scope for COPD care programs 
to generate the necessary improvements in COPD care 
does exist, providing these packages are truly compre-
hensive, multifaceted and well co-ordinated. However, 
since even the proven effective but less comprehensive 
disease management and chronic care programs struggle 
to demonstrate their economic beneﬁ  ts,7,9–11 and because 
more comprehensive programs are likely to come at an 
even higher opportunity cost than the less comprehensive 
ones, the need for rigorous studies and timely economic 
evaluations can hardly be underestimated. Furthermore, 
with innovative industries and health care practices greatly 
outpacing academic research in this area and considering 
the mounting health care costs, there is a need to estimate 
the potential cost effectiveness of COPD care programs, 
even in the absence of the ‘ideal’ clinical and economic 
data.12 This study therefore ﬁ  rst provides an update of the 
published evidence regarding the effectiveness and cost 
effectiveness of multi-component COPD care programs 
(ie, programs consisting of  2 components of disease 
management or the chronic care model). Secondly, we illus-
trate how the likely short and long term cost effectiveness 
of a particular program can be estimated with limited data 
available; the latter mainly with the aim to support timely 
decision-making, rather than providing the most precise 
estimates possible.13,14
Methods
Literature search
Medline and Cochrane databases were electronically 
searched for English-language articles published between 
January 1995 and September 2007 describing evaluations 
of disease management or chronic care model interven-
tions for adults with mild, moderate, severe, or very 
COPD.
Search terms included combinations of MeSH terms and 
text words, as described in Table 1. The search was further 
expanded by hand searching the references of identiﬁ  ed 
articles.
Study selection and data extraction
Two reviewers (KL and LS) independently selected studies 
for inclusion based on the following predetermined criteria: 
(1) interventions included at least two components of dis-
ease management as deﬁ  ned by the DMAA2 or the CCM as 
described by Wagner1 and Bodenheimer and colleagues; 15,16 
(2) studies included a control or comparison group or at least 
one outcome measured at two points in time (before/after 
designs), and (3) evaluated relevant process (ie, number of 
scheduled follow-up contacts with care providers and medica-
tion prescribing patterns); intermediate (ie, patients’ disease-
speciﬁ  c knowledge, self-efﬁ  cacy and self-management skills, 
medication compliance, and social support) or end outcomes 
(ie, mortality, quality of life, exacerbations, lung function, 
dyspnoea, symptoms, overall clinical condition, hospital 
admissions, readmissions and bed days, emergency care 
admissions, unscheduled outpatient visits, health-related 
quality of life (HRQL), days off work, COPD-related health 
care resource use and total costs for COPD-related care). 
Agreement was examined and disagreements resolved by 
consensus. Articles describing the impact of speciﬁ  c thera-
peutic regimens, such as different forms of bronchodilator 
therapy, pulmonary rehabilitation, oxygen therapy etcetera, 
were excluded because these interventions are individual 
parts of clinical guidelines and therefore beyond the scope 
of this review. Two reviewers (KL and AN) independently 
extracted the data using a standardized form created for this 
review; assessed methodological quality of the articles with 
the so called ‘HTA-DM instrument,’17 and scored this on 
a 0 to 100 scale with a score   50 points indicating poor 
quality, whilst 50 to 69 points was considered as moderate 
quality and  70 points as good quality. Articles of poor 
quality were excluded from the review.
Interventions were categorized based on (1) the setting in 
which they were carried out (ie, community, primary care, 
secondary care, tertiary care or a combination of these); 
(2) the population of COPD patients included (ie, at risk, 
mild, moderate, severe or very severe); (3) the type and 
number of intervention components (ie, self-management 
[SMAN]; delivery system design [DSYS]; decision support 
[DSUP]; clinical information systems [CIS]). As regards 
the latter we also noted whether the article explicitly named 
the intervention as being a disease management program or 
a CCM intervention. If the intervention was stated to be a 
disease management program and encompassed a clinical International Journal of COPD 2009:4 89
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Table 1 Search strategy
Combinations of MeSH and text words searched
1. “Disease management” [MeSH]
2. “Disease management”
3. “Disease state management”
4. “Delivery of Health Care, Integrated” [MeSH]
5. “Comprehensive Health Care” [MeSH:NoExp]
6.   “Patient Care Planning” [MeSH] NOT
 “Advance Care Planning” [MeSH]
7. “Primary Health Care” [MeSH] NOT “Refusal to Treat” [MeSH]
8. “Patient Care Team” [MeSH:NoExp]
9. “Critical Pathways” [MeSH]
10. “Case Management” [MeSH]
11. “Continuity of Patient Care” [MeSH]
12. “Practice Guidelines” [MeSH]
13. “Guidelines” [MeSH]
14. “Clinical Protocols” [MeSH:NoExp]
15. “Patient Education” [MeSH]
16. “Self Care” [MeSH:NoExp]
17. “Reminder systems” [MeSH]
18. “Health Education“ [MeSH]
19. “Health Promotion” [MeSH:NoExp]
20. “Community Health Planning” [MeSH]
21. “Ambulatory Care” [MeSH]
22.  (Patient OR providers) AND feedback
23.  (Patient OR providers) AND reminder
24.  (Patient OR providers) AND monitor$
25. OR/1–24
26.   “Epidemiologic Research Design” [MeSH]
  NOT “Sensitivity and Speciﬁ  city” [MeSH]
27. “Clinical  Trials” [MeSH:NoExp]
28. “Controlled Clinical Trials” [MeSH]
29. “Randomized Controlled Trials” [MeSH]
30. “Multicenter Studies” [MeSH]
31.   “Epidemiologic Studies” [MeSH] NOT
 “Seroepidemiologic Studies” [MeSH]
32. “Pilot Projects” [MeSH]
33. “Sampling Studies” [MeSH]
34. “Program Evaluation” [MeSH]
35. “Intervention Studies” [MeSH]
36. “Evaluation Studies” [MeSH:NoExp]
37. OR  26–36
38.  Controlled Clinical Trial [pt]
39. Clinical  Trial  [pt]
40.  Multicenter Study [pt]
41.  Randomized Controlled Trial [pt]
42.  Evaluation Studies [pt]
43. Meta-analysis  [pt]
44. OR  38–43
(Continued)
Table 1 (Continued)
Combinations of MeSH and text words searched
45.  37 OR 44
46. AND “Pulmonary Disease, Chronic Obstructive” [MeSH]
47. 25  AND  45
48.  Limit 47 to human
49.  Limit 48 to yr 1995–2007
50.  Limit 49 to English
information system, it was additionally registered whether 
this information system facilitated (a) population identiﬁ  ca-
tion processes [PIP]; (b) process and outcome measurement, 
evaluation and management [MEM]; and/or (c) routine 
reporting and/or feedback loops [RFEED].2
Data analysis
Extracted data were entered into a spreadsheet (Excel®; 
Microsoft, Redmond (WA), US) and analysed in a descrip-
tive way (ie, numbers, frequencies, and percentages). To 
determine the impact of the interventions, included stud-
ies were analysed for statistically signiﬁ  cant differences 
(considering the p-value as applied in the study’s analysis). 
In addition we noted whether the study was sufﬁ  ciently 
powered (ie, β   0.2) to detect a statistical signiﬁ  cant 
difference of a ‘meaningful’ size on the primary study 
outcome (with ‘meaningful’ as determined by the authors 
of the included studies). Further, where the presented data 
allowed us to, we calculated relative risks (RRs) and their 
associated 95% conﬁ  dence intervals for hospitalization, 
emergency department visits and other unplanned visits, and 
mortality. Finally, to illustrate the potential ﬁ  nancial viability 
of the COPD programs, it was explored at what opportunity 
costs a program might be expected to demonstrate a cost 
effective use of resources (1) within one year; or (2) in the 
long term (ie, over the expected remaining life time of the 
patient population) from a health system’s perspective. 
The exploration was carried out for a selection of programs 
that reported the necessary data for these analyses.
The short term cost effectiveness analysis was based on 
the reported changes in hospital and emergency department 
(re)admissions within one year of follow-up and the associ-
ated cost per hospital and/or emergency department (ED) 
admission. The long-term analysis was based on reported 
changes in survival and HRQL and evaluated against a 
range of societal willingness-to-pay (WTP) thresholds for 
one ‘quality-adjusted life year’(QALY).18,19International Journal of COPD 2009:4 90
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Results
Study retrieval
The search identified 308 nonduplicative titles. After 
independent assessment of abstracts and full-texts by two 
reviewers regarding eligibility, 288 articles were excluded 
because these (1) did not concern disease or chronic care 
management in accordance with the deﬁ  nitions of the DMAA 
or Wagner and colleagues (n = 166); or (2) were single com-
ponent interventions (n = 72); or (3) did not employ a control 
group or report more than one measurement (n = 42); or (4) 
were of poor methodological quality (n = 8). The 20 included 
articles described 17 unique COPD programs. Most articles 
originate from the US (n = 6; describing ﬁ  ve programs)20–25 
followed by Australia (n = 4)26–29 and New Zealand 
(n = 2);30,31 Canada (n = 3; describing one program)32–34 the 
Netherlands (n = 2);35,36 Spain (n = 2;37,38 one including a 
Belgian comparator group38); and China (n = 1).39
Study designs and methodological quality
The 17 studies include 14 randomized controlled trials 
(RCTs), two nonrandomized controlled trials28,30 and 
one before–after study36 (see Table 2). In 11 of the 14 
RCTs randomization was performed on the patient level, 
whereas three RCTs randomized on the level of care 
delivery centres, ie, general practices,31 nursing homes,39 
or drugstores.25
Although 15 studies report the impact of the intervention 
on resource use, only three evaluated this impact in monetary 
terms34,36,37 and can therefore be considered an economic 
evaluation. Poole and colleagues30 conducted a limited return-
on-investment analysis by investigating the reduction in bed 
days per patient needed in order to pay off the salary costs of 
the main care providers involved in the program.
Reported study follow-up varies from eight weeks37 to 
two years,22,33,35 with most articles reporting a follow-up of 
12 months (n = 9).25,28–32,34,36,38 Study sample size at baseline 
varies from n = 3230 to n = 453,25 with a mean (±SD) sample 
size of n = 163 (±104) and a median of n = 155. Average 
proportion of patient follow-up is 81% (±14%) in intervention 
arms and 78% (±16%) in control arms. Six of the 17 included 
studies demonstrate at least 80% power for detecting a mean-
ingful statistical signiﬁ  cant change in their primary outcome 
measure25,29,31,32–34,36,38 and four studies failed to include suf-
ﬁ  cient patient numbers as determined by their sample size 
calculations.20,21,27,35 Seven studies did not mention whether 
their study was sufﬁ  ciently powered,22–24,26,28,30,37,39 but three 
of these studies include less than 40 patients in each study 
arm26,28,30 and are most likely underpowered.
Methodological quality of studies is mostly moderate 
(see Table 2), with an overall mean (±SD) quality score of 
67.6 (±9.4) points and a median of 65 points. The most fre-
quently observed ﬂ  aw in included articles is that information 
on the program itself and the characteristics of the region 
or institution in which the program has been implemented 
is lacking or described too brieﬂ  y, herewith hindering the 
assessment of external validity of the ﬁ  ndings. Further, the 
time horizon of the evaluations is in almost 50% of the stud-
ies considered too short (ie, less than one year) to adequately 
capture the potential beneﬁ  ts of essentially nonpharmacologi-
cal interventions in a patient population suffering from an 
irreversible and progressing chronic condition.
Study setting and population
Most programmes are implemented in secondary care and 
three programs have been implemented across multiple set-
tings (see Table 2).
The study settings reflect the subgroups of COPD 
patients enrolled in the program, as characterized by the 
staging system of Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD).40 For example, all programs 
include patients with severe COPD (GOLD 3) who are 
commonly treated in secondary care, whereas multiple 
setting programmes encompass a broader range of patients 
(eg, GOLD 1 to 4).28,35,36
The mean age (±SD) of the included study samples 
ranges from 47.3 (±13.9)28 to 80.4 (±6.3)21 years. Across all 
included studies, the mean age is 66.4 (±7.9) with a median 
of 68.5 years.
Types of programs and included 
interventions
All programs include the components self-management 
and delivery system design. Five programs additionally 
encompass the component decision support20,21,25,32–34,39 and 
four also include clinical information systems.26,31,36,38 Of 
the four programs that are explicitly referred to as DMPs, 
three operate a clinical information system that serves to 
support process and outcomes measurement, evaluation 
and management.26,31,36 In two of these programs this system 
also facilitates routine reporting and feedback loops,26,36 and 
in one program31 the system is further used for population 
identiﬁ  cation processes.
Results on process measures
The majority of studies describing the number of scheduled 
outpatient visits and home visits reported no signiﬁ  cant International Journal of COPD 2009:4 91
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changes for general practitioner (GP), specialist or nurse 
visits (see Table 3). Medication prescribing patterns (ie, type 
and amount of COPD medication prescribed) also remained 
largely the same, except for one study that found a statistical 
signiﬁ  cant lower cost for COPD prescriptions (31% lower) 
associated with the intervention.37 The amount of patient 
education provided increased signiﬁ  cantly in all studies 
reporting this process measure. Results for coordination 
of care were mixed, depending on how coordination was 
deﬁ  ned and measured, whereas one study reported improved 
accessibility of care.36
Results on intermediate outcomes
Disease-speciﬁ  c knowledge has been found to improve 
in four out of ﬁ  ve studies measuring this.20,27,36,37 Further, 
patient reported outcomes indicated advanced techni-
cal skills (inhalation technique) and self-efficacy in 
two studies,27,37 whereas one study showed improved 
self-management and medication adherence.36 The major-
ity of studies, however, did not detect statistical signiﬁ  cant 
changes as far as self-management behaviour, medication 
compliance, technical skills/self-efﬁ  cacy and social support 
are concerned (see Table 3).
Results on end outcomes
For all reported end results, the dominating ﬁ  nding is that 
COPD care management programs generate equivalent 
outcomes in comparison to usual care and less intense 
forms of chronic care or disease management. Neverthe-
less, a few studies have detected a positive impact of their 
intervention on lung function (n = 2),25,31 physical func-
tioning (n = 3),20,22,29 and mental functioning (n = 3).22,29,39 
Furthermore, eight20,22,29–32,36,37 out of 15 studies reporting 
on HRQL ﬁ  nd statistical signiﬁ  cant improvements for (at 
least some aspects of) this parameter, although these are not 
always sustained in the longer term.22,32 As regards health 
care utilization, seven studies (eight articles)22,23,30,32,33,35,36,38 
out of 15 studies (19 articles) report a decrease in exacer-
bation related health care utilization, including ED-visits, 
hospital (re)admissions and other unscheduled outpa-
tient visits. Three studies34,36,37 presented cost data and 
showed that differences were found on individual cost 
parameters including higher costs for prescriptions,36,37 
lower hospitalization-related costs37 and lower sick leave 
costs.37 However, none of these studies reported signiﬁ  cant 
changes in total costs.
Negative findings associated with the interventions 
have also been reported. These include: deteriorated lung 
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Table 3 Reported intermediate and end outcomes: measures used and summary of ﬁ  ndings
Outcome (n, number of studies
reporting the outcome)
Measures§ Summary of ﬁ  ndings [study 
references]
Process measures
Scheduled outpatient visits (n = 7) Physician (GP) ofﬁ  ce visits[32,21,27,37,36]; Specialist/
outpatient hospital visits[32,38,37,22,36]; Nurse home 
visits[38,27,37]
+[27 (nurse home visits), 36]
=[32,38,21,27 (GP visits), 37,22 (12 month follow-up)]
−[22 (24 month follow-up)]
Medication prescriptions (n = 5) Total prescribed COPD-related medication[37,36]; 
new medications prescribed[23]; antibiotics[28,31]; 
oral steroids[28,31]; domiciliary oxygen[28]; inhaled 
bronchodilators[28]
+[37 (oxygen and nebulizer), 36]
=[37,28,31,23]
Amount of patient education provided (n = 5) Self-management education[20,36]; COPD education 
[20,21,27,24]
+[20,21,27,24,36]
Coordination of care (n = 2) Number of GP-arranged follow-ups[27]; Patient 
assessed change in coordination of care[36]
+[36]
=[27]
Accessibility of care (n = 1) Patient assessed change in accessibility of care[36] +[36]
Intermediate outcomes
Disease speciﬁ  c knowledge (n = 5) Deenen's respiratory knowledge
questionnaire[M1,36];
Self-designed questionnaire (not validated)[20,27,37,24]
+[20,27,37,36]
=[24]
Self-management behaviour (n = 4) Self-designed questionnaire (not validated)[27,35,31,36]; +[36]
Patient-reported smoking cessation[35,31,36]; physical 
activity[36]; inﬂ  uenza vaccination[27]; pneumococcal 
vaccination[27]
=[27,35,31]
Medication compliance (n = 4) Self-designed questionnaire (not validated)[37,35,36,25]; +[36]
Single-item[M2,25] and 4-point Likert scale 
questionnaire[M3,25]
=[37,35,25]
Technical skills/self-efﬁ  cacy (n = 4) COPD Self-Efﬁ  cacy Scale[M4,21,35];
Coping style questionnaire[M5, 35];
Inhalation checklist[M6, 35]; Walking self-efﬁ  cacy[M7, 22];
Self-designed questionnaire (not validated)[37]
+[37,35 (inhalation)]
=[21,35 (self-efﬁ  cacy and coping), 22]
Social support (n = 2) MOS social support survey[M8, 21,26] =[21,26 (tangible and emotional support, positive social 
interaction)]
−[26 (affectionate support)]
End outcomes
Lung function (n = 7) Post bronchodilators FEV1 (litres)[32,31,22,29];
FEV1 (% predicted)[39,31,22,29,36];
FVC (litres)[32]; FEV1/FVC (%)[32,36];
PEF rate (% predicted)[25]
+[31,25]
=[32,39,36]
−[22,29]
Dyspnoea (n = 7) MRC dyspnoea questionnaire[M9, 35];
CRQ-dyspnoea dimension[M10, 30,31,25];
UCSD Shortness of Breath Questionnaire[M11, 22]; 
Baseline and Transition Dyspnoea Indices (interview 
administered)[M12, 22];
BORG scale[M13, 23]; Self-developed questionnaire 
(not validated)[29]
=[35,30,31,29,23,25]
−[22]
Symptoms (n = 9) SGRQ-symptoms[M25, 32,21,26,27,37]; Memorial 
Symptom Assessment Scale[M26, 20]; General Health 
Questionnaire [M23, 39]; Symptoms checklist[M27, 35]; 
Self-developed questionnaire (not validated)[23]
=[20,32,21,26,27,37,35,39,23]
Physical functioning (n = 10)
=  Questionnaire based (n = 8)
SF-36 physical functioning[M14, 20,21,31]; SF-12 physical 
functioning[M15, 37]; Barthel Index[M16, 39]; RAND-36 
physical component[M17, 22];
+ [20,29]
=[21,37,39,31,22,24]
COOP (adapted physical functioning item)[M18, 29]; 
Health Status Questionnaire[M19, 24]
(Continued)International Journal of COPD 2009:4 94
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function, increased dyspnoea, increased medication use and 
longer hospital length of stay in comparison with the control 
groups. An overview of results on end outcomes is presented 
in Table 3.
Relative risks for hospitalizations, 
emergency department/unscheduled 
visits, and mortality
The observed relative risks (RRs) for hospitalization of 
intervention patients versus control patients vary widely 
(from 0.64 to 1.50; see Table 4) and only three31,32,38 are 
statistically signiﬁ  cant at a 95% conﬁ  dence interval (95% 
CI). The findings from these three studies all favour 
the intervention group. Moreover, these three programs 
include three32 chronic care components (ie, DSUP on 
top of SMAN and DSYS) or four31,38 (ie, DSUP and CIS 
in addition to SMAN and DSYS) components, whereas 
all other programs for which a RR could be calculated 
encompass SMAN and DSYS only. As regards ED and 
other unplanned outpatient visits, the RRs vary from 0.28 
to 2.28 (see Table 4), with two studies32,37 observing a 
statistical signiﬁ  cant reduction in ED-visits favouring 
the intervention. The RRs for mortality vary from 0.31 
to 1.20 (see Table 5), and none of these reach statistical 
signiﬁ  cance at a 95% CI.
Illustration 1a: Potential short term cost 
effectiveness based on reduced hospital 
admissions only
In the study of Rea and colleagues, a RR for hospital admis-
sions in the intervention group of 0.81 (95% CI: 0.59–0.83) 
was observed.31 Also the mean length of hospital stay was 
reportedly shorter in the intervention group than in the 
control group (1.1 vs 4.0 days). The cost of a hospital bed 
Table 3 (Continued)
Outcome (n, number of studies
reporting the outcome)
Measures§ Summary of ﬁ  ndings [study 
references]
=  Performance based (n = 2) 6-minute walk test[M20, 32,22]; Shuttle Walk Test[M21, 31];
Treadmill Test[22]
+[22 (12 month follow-up)]
=[32,31,22 (24 month follow-up)]
Mental functioning (n = 11) SF-36 mental health[M14, 20,21,31]; HAD[M22, 26,30]; Health 
Status Questionnaire [M19, 23]; SF-12 mental health 
[M15, 37]; General Health Questionnaire [M23, 39];
CRQ-emotion dimension [M10, 30,31,25]; CED-Depression 
Scale [M24, 22]; RAND-36 mental component [M17, 22]; 
COOP emotion components [M18, 29]
+[39,22 (12 month follow-up), 29]
=[20,21,26,37,30,31,22 (24 month follow-up), 29,23,25]
Health-related Quality of Life SF-36[M14, 20,21,31]; SGRQ-total[M25, 32,21,26,27,37,36];
CRQ-total[M10, 30,31,22,25]; Subjective Well Being 
Scale[M28, 26]; Health Status Questionnaire[M19, 23]; 
SF-12[M15, 37]; QOL-RIO[M29,35]; General Health 
Questionnaire-total[M23, 39]; Quality of Well Being 
Scale[M30, 22]; COOP-total[M18, 21]; EQ–5D[M31, 36]
+[20,32 (4 month follow-up), 37 (SGRQ),
30,31 (CRQ-fatigue and mastery),
22 (12 month follow-up), 29,36 (EQ-5D)]
=[32 (12 month follow-up), 21,26,27,37 (SF-12), 35,39,31 (SF-36),
22 (24 month follow-up), 36 (SGRQ), 25]
Health care utilization and costs (n = 19) Hospital (re)admission[32,33,38,21,26,27,37,28,39,30,31,29,23,36,25]; 
Hospital LOS[37,28,39,30,31,22]; 
ED-visits[20,32,33,21,27,37,28,39,31,22,29,23,25]; Unscheduled 
outpatient visits[32,38,21,37,22,29,23,36]; Prescriptions[37,28,31,23,36]; 
Home visits[38]; Phone calls[22]; Sick leave[36]; Total 
costs[34,37,36]
+[37 (prescriptions), 28 (hospital LOS), 36 (prescriptions)]
=[20,34,38,21,26,27,35 (outpatient visits), 28,39,30,31,
22 (ED-visits), 29,23,36 (total costs), 25]
−[32,33,38 (readmissions), 35,30 (hospital LOS),
22,23 (outpatient visits), 36]
Mortality (n = 14) All causes death[20,32,34,33,38,21,27,37,35,30,31,22,29,25] =[20,32,34,33,38,21,27,37,35,30,31,22,29,25]
Notes: §References to included studies that applied this measure are indicated numerically; References to papers describing the validity/reliability of the measure or question-
naire are indicated with Mx.
MIDeenen TAM. Patient health-education and self-management. Dissertation. Rijksuniversiteit Groningen, the Netherlands, 1996. M2Inui TS, et al Med Care. 1981;19:1061–64. 
M3Morisky DE, et al Med Care. 1986;24:67–74. M4Wigal JK, et al Chest. 1991;99:1193–6. M5Ketelaars CA,et al Thorax. 1996;51:39–43. M6Hesselink AE, et aI Scand J Prim Health Care. 
2001;19:255–60. M7Kaplan RM, et al Health Psychol 1984;3:223–42. M8Sherbourne CD, et aI Soc Sci Med. 1991;32(6):705–14. M9Bestall JC, et al Thorax. 1999;54;581–6. M10Wijkstra 
PJ, et al Thorax. 1994;49(5):465–7. Ml1Eakin EG, et al Chest. 1998;113:619–24. M12Mahler DA, et aI Chest. 1984;85:751–8. M13Borg G. Med Sci Sports Exerc. 1982;14:377–81. M14Ware 
JE, et aI Med Care. 1992;30:473–83. M15 Ware JE, et aI Med Care. 1996;34:220–33. M16Collin C, et al Int Disabil Stud. 1988;10:64–7. M17Hays RD, et al Health Econ. 1993;2:217–27. 
M18Nelson E, et al JAMA. 1983;249:3331–8. MI9Radosevich DM, et aI Health Status Questionnaire (HSQ) 2.0. Bloomington, Minn;Health Outcomes Institute, 1994. M20Borg G. 
Med Sci Sports Exerc. 1982;14:377–81. M21Singh SJ, et aI Thorax. 1992;47:1019–24. M22Zigmond AS, et al Acta Psychiatr Scan. 1983;67–6):361–70. M23Goldberg DP, et al Psychol Med. 
1979;9:139–45. M24Radloff LS. Appl Psychol Meas. 1977;1:385–401. M25Jones P, et al Am Rev Respir Dis. 1992;145:1321–7. M26Portenoy RK, et al Eur J Cancer. 1994;30A: 1326–36. 
M27Wijnhoven HA, et al Chest. 2001;119:1034–42. M28 Bradburn N.   The structure of psychological well-being. Chicago:Aldine, 1969. M29Maille AR, et al Respir Med. 1997;91:297–309. 
M30Kaplan RM et al J Chron Dis. 1984;37:85–95. M31The EuroQol Group. Health Policy. 1990;16:199–208.International Journal of COPD 2009:4 95
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day was approximately NZ$700 in 2003. From this it can 
be calculated that the average cost of hospitalization per 
COPD patient per year for the conventional care strategy 
would be:
4 * NZ$ 700 = NZ$ 2800
whereas the average annual cost of hospitalization per 
COPD patient in the intervention group would be:
0.81 * (1.1 * NZ$ 700) = NZ$ 623.7
Thus, based on the observed reduction in hospital admis-
sions and hospital length of stay, and assuming all else 
equal, a cost effective use of resources from a health systems 
perspective for this program will be achieved if it can be 
delivered in a way that the incremental costs of the program 
are lower than NZ$ 2800 – NZ$ 623.7 = NZ$ 2176.3 per 
patient per year.
Illustration 1b: Potential short term cost 
effectiveness based on changes in hospital 
admission and ED visits
In the study of Hermiz and colleagues,27 a RR for hospital 
admissions of 1.27 (95% CI: 0.66–2.43) and a RR for 
ED visits of 0.28 (95% CI: 0.06–1.27) was observed 
for the intervention group as compared for the controls. 
The cost of a hospital bed is approximately AUS$ 320 
and the costs of an ED visit AUS$ 100.41 Assuming 
the length of hospital stay is 2.4 days41 and is equal in 
COPD care management and usual care, the average cost 
of hospitalizations per patient per year in a usual care 
strategy would be:
2.4 * AUS$ 320 = AUS$ 768
Further, assuming an average of 0.5 ED visits per COPD 
patient per year,41 the cost of ED visits in a usual care strategy 
would be:
0.5 * AUS$ 100 = AUS$ 50
In the COPD care program, the annual cost of hospitaliza-
tions per patient would be:
1.27 * (2.4 * AUS$ 320) = AUS$ 975.36
and the average annual cost of ED visits per COPD patient 
would be:
0.28 * (0.5 * AUS$ 100) = AUS$ 14
Based on the observed increase in hospital admissions and 
reduction in ED visits, and assuming all else equal, this COPD 
program would be considered cost effective from a health 
systems perspective if its incremental costs would be lower than 
AUS$ 818 – AUS$ 989.36 = − AUS$ 171.36 per patient per 
year. This means that on other aspects of the program savings of 
at least AUS$ 171.36 per patient per year should be generated 
in order to set off the additional hospitalization costs, and even 
more to potentially achieve a return on investment.42
Table 4 Relative risks of hospitalization and emergency department (ED)/unscheduled visits for intervention patients versus control 
patients
Source Study setting Included
GOLD-stages
Number of 
components
Relative risk of 
hospitalization 
(95% Conﬁ  dence 
interval)
Relative risk of EDI
unscheduled visits 
(95% Conﬁ  dence 
interval)
Bourbeau et al (2003)32 Secondary care 2 and 3 3 0.64 (0.45–0.91) 0.64 (0.48–0.86)
Casas et al (2006)38 Tertiary care 3 and 4 4 0.67 (0.49–0.91) NA
Gourley et al (1998)24 Secondary care 3 and 4 2 NA 1.12 (0.44–5.43)
Hermiz et al (2002)27 Community and 
primary care
2 and 3 2 1.27 (0.66–2.43) 0.28 (0.06–1.27)
Hernandez et al (2003)37 Secondary and 
tertiary care
2 and 3 2 0.74 (0.45–1.21) 0.44 (0.22–0.86)
Jeffs et al (2005)28 Secondary care 1–4 2 1.50 (0.84–2.67) NA
Poole et al (2001)30 Secondary care 3 2 1.08 (0.75–1.57) NA
Rea et al (2004)31 Primary care 2 and 3 4 0.81 (0.59–0.83) 0.46 (0.16–1.37)
Smith et al (1999)29 Secondary care 3 2 1.01 (0.82–1.26) 2.28 (0.96–5.43)International Journal of COPD 2009:4 96
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Illustration 2a: Potential long term
cost effectiveness based on changes
in health-related quality of life only
The study of Steuten and colleagues reports an increase in 
HRQL of 0.02 (from 0.67 at baseline to 0.69 at 12 months 
follow-up).36 Assuming 1) no difference in mortality between 
usual care and the intervention; 2) an average life expectancy 
of 75 years (ie, plus 14 years from the sample’s baseline age 
of 61 years); and 3) a sustained relative intervention effect on 
HRQL over the life time of a patient, then, all else equal, the 
incremental QALYs over the remaining life time of one patient 
in the intervention versus the control strategy would be:
14 * 0.02 = 0.28 QALYs1*
At a societal WTP of  30,000 per QALY this means that the 
program would be considered cost effective if its incremental 
costs do not exceed 0.28 *  30,000 =  8400 per patient over 
his/her remaining lifetime or on average  600 per patient per 
year ( 8400/14). Similarly, if the WTP for a QALY would 
be  50,000 then the cost effectiveness gap for the program, 
given its incremental effectiveness on HRQL of 0.28, would 
be as high as  14,000 per patient over his/her remaining 
lifetime (or  1,000 annually) and at a WTP of  20,000 only 
5600 over lifetime (or  400 per year).
Illustration 2b: Potential long term cost 
effectiveness based on changes in health 
related quality of life and survival
From the paper of Hernandez and colleagues,37 it can be 
derived that the average score on the physical component of 
the Short Form 12 (SF-12) is 0.3770 in the intervention group 
and 0.3590 in the control group (scores converted from a 0–100 
to a 0–1 scale). The incremental HRQL for the interventions 
group on the physical domain is thus +0.0180. On the mental 
domain of the SF12, the average scores are 0.4600 and 0.4395 
in the intervention and control group respectively, thus an 
incremental HRQL for the intervention group of  0.0205 on 
the mental domain. It is assumed that the incremental and 
physical domains are additive.43 Given that the average age of 
the study subjects is 71 years at baseline, the RR for mortality 
is 0.6 for intervention vs control group, and assuming an aver-
age life expectancy of 75 years when receiving conventional 
care (so +4 years from baseline), then, all else equal, the mean 
difference in QALYs over the remaining life time of one patient 
in the intervention versus the usual care strategy would be:
(4/0.6) * (0.0180 + 0.0205) = 6.66676 * 0.03085 = 0.256
 QALYs2*
At a societal WTP of  30,000 per QALY this means that the 
program would be considered cost effective if its incremental 
Table 5 Relative risks of mortality for intervention patients versus control patients
Source Study setting Included 
GOLD-stages
Number of
components
Relative risk
(95% Conﬁ  dence 
interval)
Aiken et al (2006)20 Tertiary care 3 and 4 3 1.20 (0.60–2.40)
Bourbeau et al (2003)32 Secondary care 2 and 3 3 0.56 (0.19–1.60)
Casas et al (2006)38 Tertiary care 3 and 4 4 1.19 (0.59–2.39)
Coultas et al (2005)21 Primary care 2 and 3 4 1.01 (0.21–4.86)*
Gadoury et al (2005)33 Secondary care 2 and 3 3 0.71 (0.37–1.38)
Hermiz et al (2002)27 Community and 
primary care
2 and 3 2 1.00 (0.43–2.33)
Hernandez et al (2003)37 Secondary and 
tertiary care
2 and 3 2 0.60 (0.20–1.82)
Poole et al (2001)30 Secondary care 3 2 0.33 (0.04–2.87)
Rea et al (2004)31 Primary care 2 and 3 4 0.31 (0.26–1.65)
Ries et al (2003)22 Tertiary care 3 2 0.98 (0.43–2.22)
Smith et al (1999)29 Secondary care 3 2 1.14 (0.45–2.90)
Note: *RR for case management versus usual care.
1,*For reasons of simplicity, future beneﬁ  ts and costs are not discounted 
in this illustration.
2,*For reasons of simplicity, future beneﬁ  ts and costs are not discounted 
in this illustration.International Journal of COPD 2009:4 97
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costs would not exceed 0.256 *  30,000 =  7680 per patient 
over his/her expected lifetime of 6.7 years. At a WTP 
of  50,000 the cost effectiveness gap would be  12,800 and 
at a WTP of  20,000 this gap would be  5,120 per patient 
over the expected lifetime.
Discussion
Notwithstanding their relentless efforts and investments, 
the innovators behind chronic care programs for people 
with COPD keep struggling to articulate the value of these 
programs to patients, care providers and payers in terms of 
‘proof’ rather than ‘belief’. This study therefore aimed to 
update and critically review the current evidence base as 
regards the impact of multi-component COPD care programs 
on process, intermediate and end results of care. Further-
more, in order to support timely decision-making regarding 
(further) investment in such programs, we illustrated how 
potentially cost effective programs can be identiﬁ  ed, even in 
the absence of full-blown health economic evaluations.
Starting with the effectiveness of multi-component COPD 
programs on processes and intermediate outcomes of care, 
we ﬁ  nd little evidence of signiﬁ  cant improvements. Although 
signiﬁ  cantly more patient self-management education is 
provided as part of the COPD programmes, and patient’s 
disease-speciﬁ  c knowledge indeed improves as a result of 
this, on the whole there is little proof that this better knowl-
edge actually translates into signiﬁ  cant and sustained behav-
ioural changes, as for example smoking cessation, or in better 
medication adherence and self-efﬁ  cacy within one or two 
years follow-up. This ﬁ  nding is in accordance with results 
from previous reviews,11,44 but nevertheless dissatisfying. 
Since smoking cessation is still regarded the most effective 
way to slow down the disease progression, more emphasis 
should be placed on other ways to encourage smokers to quit 
than purely providing education. Reimbursing the costs of 
smoking cessation therapy, for example, has been proven an 
efﬁ  cacious45 and cost effective46 way to signiﬁ  cantly increase 
the prolonged abstinence rate.
Also on end outcomes of care (including clinical 
outcomes, dyspnoea, symptoms and physical and mental 
functioning, HRQL, mortality, health care utilizations 
and costs), the COPD care programs merely demonstrate 
equivalence to usual care. As regards hospital (re)admissions, 
which are commonly the primary outcome of evaluation, 
it is worth noting that only for the three programs that 
encompass  3 components of chronic care management, 
the associated RRs for hospital readmission were statistically 
signiﬁ  cant, and favoured the intervention strategy, whereas 
for programs encompassing two components no statistical 
signiﬁ  cant changes were detected. Given that the patient 
populations included in these studies were comparable to 
the other studies in terms of sample size, COPD severity 
and age, and that all programs encompassed the components 
‘delivery system design’ and ‘self-management support’, this 
might suggest that programs that additionally encompass the 
components ‘clinical information system’ and/or ‘decision-
support’ are more likely to be effective in reducing hospital 
(re)admissions than the more limited packages. Although 
this suggestion should be interpreted with caution since the 
programs were not compared head to head and RRs could 
only be calculated for nine of the 17 studies, this may start to 
shed more light on the important issues raised in the review 
of Adams and colleagues11 about the relative value of each of 
the chronic care components for COPD, and the incremental 
value of combining more than two components in one COPD 
program. Further, the fact that the component ‘decision-sup-
port’ is lacking in most programs might indicate that clinical 
guidelines, which have shown to reduce unjustiﬁ  ed variety 
in care and improve delivery of cost effective care, are still 
underused. A possible explanation for this is that most guide-
lines focus more on decision-making by individual profes-
sionals than on such multi-disciplinary care processes.47 As 
such, this points out the responsibility for health professionals 
and care managers to intensify their efforts for developing 
and implementing such multidisciplinary decision-support 
tools as part of their COPD programs.
As regards HRQL, about half of the studies reporting 
this outcome observed statistical signiﬁ  cant improvements 
on (limited) aspects of quality of life, but it was not always 
clear whether these improvements exceeded the minimal 
clinically meaningful difference. Moreover, the studies of 
Bourbeau and colleagues34 and Ries and colleagues22 showed 
that the positive impact did not sustain over time. Neverthe-
less, no studies reported a deterioration in HRQL and also 
there seemed to be no relation with the COPD severity of 
the included population or the setting in which the program 
was implemented. The latter is in contrast with a previous 
review of Niesink and colleagues,48 concluding that improved 
HRQL resulting from COPD disease management is limited 
to programs that are (at least partly) implemented in primary 
care.
Since only three studies undertook a (partial) economic 
evaluation, and the programs differ largely in terms of their 
contents as well as in the way they are operated in daily 
practice, the extent to which COPD care programs deliver 
value-for-money could not convincingly be demonstrated International Journal of COPD 2009:4 98
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at the aggregate level. The provided illustrations on the 
potential cost effectiveness of speciﬁ  c COPD programs, 
however, may help to indicate whether there is sufﬁ  cient 
opportunity for the program to be considered a worthwhile 
spending of scarce resources or to deliver a return on invest-
ment in the short or longer term. Although the illustrations 
are deliberately kept simple and therefore the ﬁ  gures should 
not be taken at face value, they do suggest that there is 
a fairly limited scope for the programs to save money or 
break-even. Again, similar observations have been published 
previously as well as reasons why this might be the case. 
Linden and Adler-Milstein12 for example point out that 
“the main opportunity for chronic care programs to realize 
short-term medical cost savings is via reductions in costly 
and avoidable hospital admissions” and “a focus on avoiding 
the ﬁ  rst admission during the intervention period is critical 
given that hospitalizations are relatively rare events for the 
majority of the population” and that “individuals may only 
experience one over the entire course of the program.” There-
fore, close patient monitoring and effective integrated care 
delivery across community, primary, secondary and tertiary 
care are crucial to pick up exacerbation signs more timely 
and respond more pro-actively to achieve the desired cost 
effectiveness target. However, when having a closer look 
at the programs included in this review, it can be seen that 
only three are characterized by some degree of integration 
between care settings, whereas the majority is aimed at sec-
ondary care only, and therefore after the ﬁ  rst hospitalization. 
As regards the disease severity of the included populations a 
similar observation can be made: most programs focus on the 
sicker part of the population, ie, GOLD stage 3. Of course, 
in a sicker population with higher hospitalization rates, a 
relatively lower number of admissions need to be avoided 
for the program to break even. But, such a narrowly focused 
program addresses only a small part of the population in a 
too late stadium to achieve the long term goal of chronic 
care management, which is reducing the increasing burden 
of COPD on society.
Finally, a couple of limitations of this review have to 
be taken into account when interpreting its results. First, 
determining whether a program consisted of two or more 
components was complicated by the fact that some papers 
only provided a limited description of their intervention. 
In case of doubt the paper was excluded and this may 
conservatively have limited the sample of included papers. 
However, when comparing the number of included studies 
in our review (ie, 20 studies) with the review of Adams 
and colleagues11 (n = 37) that also considered single 
component studies, the amount of included papers seems 
reasonable. Moreover, the multi-component programs 
included by Adams and colleagues11 were also picked up 
by our search. Finally, the results of this review should 
be interpreted in the light of the moderate methodological 
quality of its underlying studies, including for example 
at least seven studies that were underpowered to detect 
meaningful and statistical signiﬁ  cant changes, as well 
as the lack of economic evaluations in the existing evi-
dence base. Although the currently published data can be 
used to provide some indication about the potential cost 
effectiveness of COPD care programs, more and better 
health economic information will be needed to reduce 
uncertainty regarding the real impact of COPD care pro-
grams in daily practice. To obtain this, well-designed but 
practical multicentre health economic studies including 
broad representative patient samples, should be performed 
across care settings.49–50
Conclusion
This systematic review shows that identifying potentially cost 
effective multi-component COPD care programs remains a 
challenge given the scarcity of methodologically sound stud-
ies that demonstrate signiﬁ  cant improvements on process, 
intermediate and end results of care. Nevertheless, also in 
the absence of ‘perfect data’, decisions regarding (future) 
investments in such care programs have to be made, and will 
be made, with the information that is available today. Esti-
mations of potential cost effectiveness of speciﬁ  c programs 
as illustrated in this paper might support decision-makers 
in doing so. Further research, however, is needed to, ﬁ  rstly, 
substantiate the ﬁ  nding of this study that programs includ-
ing three or more chronic care components are likely to 
be more cost effective than programs that only include the 
components ‘delivery system design’ and ‘self-management 
support’. Finally it is recommended to carefully investigate 
whether programs that are more strongly based on multi-
disciplinary guidelines will indeed deliver more value for 
money than the current COPD care programs, especially 
when implemented across care settings and including broader 
patient samples.
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